Frontier Pharma: Schizophrenia and Associated Indications Report 2016 - Weak Pipeline Means Future Schizophrenia Market May Look to Treatment for Similar Indications - Research and Markets

DUBLIN, May 12, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Frontier Pharma: Schizophrenia and Associated Indications - Small but Diverse Range of First-in-Class Molecular Targets Hold Promise for Treatment of Negative and Cognitive Symptoms" report to their offering.

Schizophrenia is a severe mental disorder that is characterized by abnormal social behavior and failure to recognize what is real; its symptoms are broadly divided into positive, negative and cognitive. The treatment of schizophrenia is multi-factorial and includes medical, psychological and psychosocial inputs. Antipsychotic medication is the main pharmacological agent used, along with counselling, job training, and social rehabilitation.

Both typical and atypical antipsychotics are used, and the choice of medication is usually left to the discretion of the treating physician. Clozapine, which is an atypical antipsychotic that binds to serotonin and dopamine receptors, is often given to patients who do not improve with other antipsychotics.

Current treatments, although effective for positive symptoms, have not proven as effective for negative symptoms and cognitive dysfunction, nor are there are any disease-modifying drugs currently available. The pipeline for schizophrenia is small, particularly given the large patient population, it also has low levels of innovation in comparison to other psychiatric indications in the pharmaceutical industry.

However, the overall level of innovation in the pipeline for schizophrenia-related indications (which includes depression, panic disorders, obsessive compulsive disorder, post-traumatic stress disorder and cognitive deficit) is far higher, with these related products having the potential to provide some benefit to patients with schizophrenia.

Scope

• The current clinical landscape of schizophrenia
• - What is the pathophysiology of schizophrenia?
• - How is schizophrenia diagnosed?
• - What are the current treatment options?
• The schizophrenia pipeline is small, although there is a much larger pipeline for its related indications.
• - What are the common targets and mechanisms of action of pipeline therapies?
• - Will the pipeline address unmet needs such as a lack of diverse treatment options for schizophrenia patients, particularly those with negative or cognitive symptoms?
• - What is the composition of the pipeline for schizophrenia-related indications, and will they be of benefit to schizophrenia patients?
• First-in-class products and targets currently within the schizophrenia pipeline
• - What are the most promising first-in-class targets for schizophrenia?
• Detailed outlook on first-in-class targets and whether they have other therapeutic potential across the industry
• Licensing deals are the most common form of strategic alliance in schizophrenia
• - How do deal frequency and value compare between target families and molecule types?
• - How do licensing and co-development deals compare between first-in-class and non-first-in-class profiles?

Key Topics Covered:

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Executive Summary

2.1 A Complex and Poorly Understood Disorder, with Numerous Unmet Needs

2.2 Small Pipeline for Schizophrenia with Few Signs of Innovation

2.3 Extensive Pipeline for Associated Indications

3 The Case for Innovation

3.1 Growing Opportunities for Biologic Products

3.2 Diversification of Molecular Targets

3.3 Innovative First-in-Class Product Developments Remain Attractive

3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation

3.5 Report Guidance

4 Clinical and Commercial Landscape

4.1 Disease Overview

4.2 Epidemiology

4.3 Disease Etiology

4.4 Disease Pathophysiology

4.4.1 Susceptibility Genes

4.4.2 Neurotransmission Alterations

4.4.3 Phosphatidylinositol Signaling

4.5 Disease Symptoms

4.6 Indications Associated With Schizophrenia

4.6.1 Panic Disorder

4.6.2 Depression

4.6.3 Post-Traumatic Stress Disorder

4.6.4 Obsessive Compulsive Disorder

4.6.5 Cognitive Impairment

4.7 Diagnosis

4.8 Prognosis

4.9 Treatment Options

4.10 Overview of Marketed Products

4.10.1 Molecule Type and Target Analysis

4.11 Current Unmet Needs

5 Assessment of Pipeline Product Innovation

5.1 Schizophrenia Pipeline by Molecule Type, Phase and Therapeutic Target

5.2 Comparative Distribution of Programs between Schizophrenia Disease Market and Pipeline by Therapeutic Target Family

5.3 First-in-Class Pipeline Programs

6 Schizophrenia Pathophysiology and Innovation Alignment

6.1 The Complexity of Signaling Networks in the Central Nervous System

6.2 First-in-Class Target Matrix Assessment

7 First-in-Class Target Evaluation

7.1 Pipeline Programs Targeting D-Amino Acid Oxidase

7.2 Pipeline Programs Targeting Gamma-Aminobutyric Acid Receptor, Subunit Alpha 5

7.3 Pipeline Programs Targeting Glutamate Carboxypeptidase 2

7.4 Pipeline Programs Targeting Phosphodiesterase 9

7.5 Pipeline Programs Targeting Potassium Voltage-Gated Channel Subfamily C, Member 1

7.6 Pipeline Programs Targeting Probable G Protein-Coupled Receptor 52

7.7 Pipeline Programs Targeting G Protein-Coupled Receptor 78

7.8 Pipeline Programs Targeting Probable G Protein-Coupled Receptor 85

7.8.1 Pipeline Programs Targeting Pipeline Programs Targeting Probable G Protein-Coupled Receptor 173

7.8.2 Pipeline Programs Targeting Pipeline Programs Targeting Probable G Protein-Coupled Receptor 27

7.9 Pipeline Programs Targeting Sodium and Chloride Dependent Glycine Transporter 1

7.10 Pipeline Programs Targeting Trace Amine-Associated Receptor 1

7.11 Conclusion

8 Deals and Strategic Consolidations

8.1 Licensing Deals

8.2 Co-development Deals

8.3 First-in-Class Programs not Involved in Licensing or Co-development Deals

9 Appendix

For more information visit

http://www.researchandmarkets.com/research/f2zc7v/frontier_pharma

Media Contact:

Research and Markets

Laura Wood, Senior Manager

[e-mail]

For E.S.T Office Hours Call [phone]

For U.S./CAN Toll Free Call [phone]

For GMT Office Hours Call [phone]

U.S. Fax: [phone]

Fax (outside U.S.): [phone]